Endevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1s July 7, 2026Posted inBiotechnology Clinical-stage Kalohexis is readying a public listing to support its obesity and cancer cachexia treatments. Post navigation Previous Post Boehringer bags PVT’s viral vector platform for cancer vaccine R&DNext PostWhitehawk swoops in for five ADCs via development deal with China’s Biocytogen
